ACUMEN PHARMACEUTICALS INC (ABOS)
US00509G2093 - Common Stock
Overall ABOS gets a fundamental rating of 1 out of 10. We evaluated ABOS against 572 industry peers in the Biotechnology industry. While ABOS seems to be doing ok healthwise, there are quite some concerns on its profitability. ABOS has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
ABOS had negative earnings in the past year.
In the past year ABOS has reported a negative cash flow from operations.
ABOS had negative earnings in each of the past 5 years.
In the past 5 years ABOS always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of ABOS (-30.59%) is better than 67.43% of its industry peers.
ABOS's Return On Equity of -37.60% is fine compared to the rest of the industry. ABOS outperforms 73.81% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.59% | ||
| ROE | -37.6% | ||
| ROIC | N/A |
ROA(3y)-27.46%
ROA(5y)-40.85%
ROE(3y)-29%
ROE(5y)-46.88%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for ABOS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, ABOS has more shares outstanding
The debt/assets ratio for ABOS is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -0.68, we must say that ABOS is in the distress zone and has some risk of bankruptcy.
ABOS's Altman-Z score of -0.68 is fine compared to the rest of the industry. ABOS outperforms 60.53% of its industry peers.
A Debt/Equity ratio of 0.14 indicates that ABOS is not too dependend on debt financing.
ABOS has a worse Debt to Equity ratio (0.14) than 67.61% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.14 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.68 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 10.43 indicates that ABOS has no problem at all paying its short term obligations.
With an excellent Current ratio value of 10.43, ABOS belongs to the best of the industry, outperforming 82.30% of the companies in the same industry.
A Quick Ratio of 10.43 indicates that ABOS has no problem at all paying its short term obligations.
ABOS has a Quick ratio of 10.43. This is amongst the best in the industry. ABOS outperforms 82.30% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 10.43 | ||
| Quick Ratio | 10.43 |
3. Growth
3.1 Past
The earnings per share for ABOS have decreased strongly by -22.32% in the last year.
EPS 1Y (TTM)-22.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-108.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, ABOS will show a very negative growth in Earnings Per Share. The EPS will decrease by -11.44% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-49.22%
EPS Next 2Y-32.47%
EPS Next 3Y-22.47%
EPS Next 5Y-11.44%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ABOS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ABOS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as ABOS's earnings are expected to decrease with -22.47% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-32.47%
EPS Next 3Y-22.47%
5. Dividend
5.1 Amount
No dividends for ABOS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ACUMEN PHARMACEUTICALS INC
NASDAQ:ABOS (1/14/2025, 8:21:39 PM)
After market: 1.56 0 (0%)1.56
-0.03 (-1.89%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners78.42%
Inst Owner Change0%
Ins Owners5.52%
Ins Owner Change8.97%
Market Cap93.72M
Analysts86.67
Price Target11.02 (606.41%)
Short Float %2.92%
Short Ratio5.22
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-26.67%
Min EPS beat(2)-34.3%
Max EPS beat(2)-19.05%
EPS beat(4)1
Avg EPS beat(4)-13.3%
Min EPS beat(4)-34.3%
Max EPS beat(4)5.73%
EPS beat(8)4
Avg EPS beat(8)-2.9%
EPS beat(12)4
Avg EPS beat(12)-21.43%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-3.57%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-48.15%
EPS NY rev (1m)0%
EPS NY rev (3m)-19.55%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.43 | ||
| P/tB | 0.43 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.37
EYN/A
EPS(NY)-1.9
Fwd EYN/A
FCF(TTM)-1.12
FCFYN/A
OCF(TTM)-1.12
OCFYN/A
SpS0
BVpS3.62
TBVpS3.62
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.59% | ||
| ROE | -37.6% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-27.46%
ROA(5y)-40.85%
ROE(3y)-29%
ROE(5y)-46.88%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.14 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 38.57% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 10.43 | ||
| Quick Ratio | 10.43 | ||
| Altman-Z | -0.68 |
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-22.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-108.33%
EPS Next Y-49.22%
EPS Next 2Y-32.47%
EPS Next 3Y-22.47%
EPS Next 5Y-11.44%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-63.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-80.26%
EBIT Next 3Y-25.65%
EBIT Next 5YN/A
FCF growth 1Y-142.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-143.98%
OCF growth 3YN/A
OCF growth 5YN/A